New directions in the management of severe lupus nephritis

Minerva Urologica e Nefrologica

Volumn 58, Issue 1, 2006, Pages 29-38

  Lenz, O ^a,b   Fornoni, A ^a   Contreras, G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Div of Nephrology and Hypertension   (United States)

Author keywords

Kidney; Lupus Erythematosus, Systemic; Lupus nephritis

Indexed keywords

ABETIMUS; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE DERIVATIVE; CALCIUM; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE DERIVATIVE; CYCLOSPORIN A; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10 ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; OKT 4; PRASTERONE; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VITAMIN D;

ACUTE GLOMERULONEPHRITIS; AMENORRHEA; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; DRUG USE; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; META ANALYSIS; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARY INSUFFICIENCY; PATHOGENESIS; PATIENT COMPLIANCE; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SMOKING CESSATION; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

CYCLOPHOSPHAMIDE; DRUG EVALUATION, PRECLINICAL; HUMANS; LUPUS NEPHRITIS; SEVERITY OF ILLNESS INDEX;

EID: 33744999183     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413-24.
2. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299-308.
3. Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK. Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 1995;95:531-41.
4. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993;177:1367-81.
5. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:191-201.
6. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1241-50.
7. Klinman DM, Shirai A, Ishigatsubo Y, Conover J, Steinberg AD. Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus. Arthritis Rheum 1991;34:1404-10.
8. Linker-Israeli M, Quismorio FP Jr, Horwitz DA. CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990;33:1216-25.
9. Bakke AC, Kirkland PA, Kitridou RC, Quismorio FP Jr, Rea T, Ehresmann GR et al. T lymphocyte subsets in systemic lupus erythematosus. Correlations with corticosteroid therapy and disease activity. Arthritis Rheum 1983;26:745-50.
10. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
11. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62.
12. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
13. El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003;12:692-6.
14. Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002.
15. Austin HA, III, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
16. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50.
17. Gourley MF, Austin HA, III, Scott D, Yarboro CH, Vaughan EM, Muir J et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-57.
18. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
19. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997;29:193-9.
20. Flanc RT, Roberts MA, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled clinical trials. Am J Kidney Dis 2004;43:197-208.
21. Boumpas DT, Austin HA, III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
22. Chan TM, Li FK, Wong RW, Wong KL, Chan KW, Cheng IK. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995;71:321-7.
23. Aspreva Pharmaceuticals. Aspreva Lupus Management Study (ALMS) (NCT00121082). Available at http://www.clinicaltrials.gov.
24. Houssiau FA, Jadoul M. Cytotoxic therapy of lupus nephritis: recent developments. Nephrol Dial Transplant 2002;17:955-7.
25. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed ER, Danieli MG et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
26. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon GE, Danieli MG et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-40.
27. Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS et al. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001;38:256-64.
28. National Cancer Institute. Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus (NCT00076752). Available at http://www.clinicaltrials.gov.
29. Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 2000;356:701-7.
30. Traynor AE, Barr WG, Rosa RM, Rodriguez J, Oyama Y, Baker S et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 2002;46:2917-23.
31. Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003;48:166-73.
32. Cade R, Spooner G, Schlein E, Pickering M, DeQuesada A, Holcomb A et al. Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron 1973;10:37-56.
33. Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. Ann Intern Med 1975;83:597-605.
34. Nossent HC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000;39:969-74.
35. van den Wall Bake AW, Berden JH, Derksen RH, Glas-Vos JW, Hagen EC. Therapy of proliferative lupus glomerulonephritis: a prospective trial in The Netherlands. Neth J Med 1994;45:280-4.
36. Dinant HJ, Decker JL, Klippel JH, Balow JE, Plotz PH, Steinberg AD. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med 1982;96:728-36.
37. Ginzler E, Diamond H, Guttadauria M, Kaplan D. Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. Arthritis Rheum 1976;19;693-9.
38. Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999;10:833-9.
39. Karim MY, Alba P, Cuadrado MJ, Abbs IC, D'Cruz DP, Khamashta MA et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002;41:876-82.
40. Kingdon EJ, McLean AG, Psimenou E, Davenport A, Powis SH, Sweny P et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001;10:606-11.
41. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001;28:2103-8.
42. Fu YF, Liu GL. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine. Clin Nephrol 2001;55:318-21.
43. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999;8:731-6.
44. Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998;31:213-7.
45. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998;32:318-22.
46. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84.
47. Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A et al. Long-term treatment of lupus nephritis with cyclosporin A. QJM 1998;91:573-80.
48. Dostal C, Tesar V, Rychlik I, Zabka J, Vencovsky J, Bartunkova J et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 1998;7:29-36.
49. Entani C, Izumino K, Iida H, Fujita M, Asaka M, Takata M et al. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. Nephron 1993;64:471-5.
50. Duddridge M, Powell RJ. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997;56:690-2.
51. Boumpas DT, Tassiulas IO, Fleisher TA, Vaughan E, Piscitelli S, Kim Y et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin Nephrol 1999;52:67-75.
52. Davis JC Jr, Austin H III, Boumpas D, Fleisher TA, Yarboro C, Larson A et al. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 1998;41:335-43.
53. Jones BM, Liu T, Wong RW. Reduced in vitro production of interferon-gamma, interleukin-4 and interleukin-12 and increased production of interleukin-6, interleukin-10 and tumour necrosis factor-alpha in systemic lupus erythematosus. Weak correlations of cytokine production with disease activity. Autoimmunity 1999;31:117-24.
54. Calvani N, Satoh M, Croker BP, Reeves WH, Richards HB. Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus. Kidney Int 2003;64:897-905.
55. Kikawada E, Lenda DM, Kelley VR. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology. J Immunol 2003;170:3915-25.
56. Carvalho-Pinto CE, Garcia MI, Mellado M, Rodriguez-Frade JM, Martin-Caballero J, Flores J et al. Autocrine production of IFN-gamma by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice. J Immunol 2002; 169:1058-67.
57. Miyake K, Nakashima H, Akahoshi M, Inoue Y, Nagano S, Tanaka Y et al. Genetically determined interferon-gamma production influences the histological phenotype of lupus nephritis. Rheumatology 2002;41:518-24.
58. Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine 1998;10:140-7.
59. Yoshio T, Masuyama JI, Kohda N, Hirata D, Sato H, Iwamoto M et al. Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J Rheumatol 1997;24:489-95.
60. al Janadi M, al Dalaan A, al Balla S, al Humaidi M, Raziuddin S. Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis. J Clin Immunol 1996;16:198-207.
61. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800.
62. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
63. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
64. National Institute of Diabetes and Digestive and Kidney Diseases. Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy (NCT00050713). Available at http://clinicaltrials.gov.
65. Isaacs JD. From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies. Rheumatology 2001;40:724-38.
66. Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003;3:323-8.
67. Choy EH, Panayi GS, Emery P, Madden S, Breedveld FC, Kraan MC et al. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology 2002;41:1142-8.
68. Moreland LW, Alten R, Van den BF, Appelboom T, Leon M, Emery P et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-9.
69. Hiepe F, Volk HD, Apostoloff E, von Baehr R, Emmrich F. Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody. Lancet 1991;338:1529-30.
70. Dharnidharka VR. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:2085-6.
71. Wofsy D, Diamond B. Treating systemic lupus erythematosus (SLE) patients with CTLA4-IgG4m (RG2077) (NCT00094380). Available at http://www.clinicaltrials. gov.
72. Schiffer LE, Hussain N, Wang X, Huang W, Sinha J, Ramanujam M et al. Lowering anti-dsDNA antibodies: what's new? Lupus 2002;11:885-94.
73. Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996;157:3159-64.
74. Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001;28:95-101.
75. Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001;28:257-65.
76. Strand V, Aranow C, Cardiel MH, Alarcon-Segovia D, Furie R, Sherrer Y et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003;12:677-86.
77. Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-54.
78. Burt, R. Cyclophosphamide and CAMPATH in Patients With Systemic Lupus Erythematosus (NCT00278538). Available at http://www.clinicaltrials.gov.
79. Genentech. A Study to evaluate the efficacy and safety of rituximab in subjects with ISN/RPS class III or IV lupus nephritis (NCT00282347). Available at http://www.clinicaltrials.gov.
80. Lucas JA, Ahmed SA, Casey ML, MacDonald PC. Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone. J Clin Invest 1985;75:2091-3.
81. van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 1999;8:181-7.
82. van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826-31.
83. Schulze M, Donadio JV Jr, Pruchno CJ, Baker PJ, Johnson RJ, Stahl RA et al. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int 1991;40:533-8.
84. Kusunoki Y, Akutsu Y, Itami N, Tochimaru H, Nagata Y, Takekoshi Y et al. Urinary excretion of terminal complement complexes in glomerular disease. Nephron 1991;59:27-32.
85. Shernan SK, Fitch JC, Nussmeier NA, Chen JC, Rollins SA, Mojcik CF et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2004;77:942-9.
86. De Vries B, Matthijsen RA, Wolfs TG, Van Bijnen AA, Heeringa P, Buurman WA. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation 2003;75:375-82.
87. Banda NK, Kraus D, Vondracek A, Huynh LH, Bendele A, Holers VM et al. Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum 2002;46:3065-75.
88. Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs 2002;3:1017-23.
89. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002;136:604-15.
90. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003;:S207-10.
91. Orth SR. Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function. J Am Soc Nephrol 2004;15:S63.
92. Espinoza LR. Antiphospholipid antibody syndrome: treatment. Lupus 1996;5:456-7.
93. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ. Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
94. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59:260-9.
95. Ruggenenti P, Brenner BM, Remuzzi G. Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron 2001;88:254-9.
96. Clark WF, Moist LM. Management of chronic renal insufficiency in lupus nephritis: role of proteinuria, hypertension and dyslipidemia in the progression of renal disease. Lupus 1998;7:649-53.
97. de Deus RB, Ferreira AC, Kirsztajn GM, Heilberg IP. Osteopenia in patients with glomerular diseases requiring long-term corticosteroid therapy. Nephron Clinical Practice 2003;94:c69-c74.
98. Joy MS, Neyhart CD, Dooley MA. A multidisciplinary renal clinic for corticosteroid-induced bone disease. Pharmacotherapy 2000;20:206-16.
99. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987;83:877-85.
100. Joseph RE, Radhakrishnan J, Appel GB. Antiphospholipid antibody syndrome and renal disease. Curr Opin Nephrol Hypertens 2001;10:175-81.
101. Cheigh JS, Stenzel KH. End-stage renal disease in systemic-lupus erythematosus. Am J Kidney Dis 1993;21:2-8.
102. Moroni G, Tantardini F, Ponticelli C. Renal replacement therapy in lupus nephritis. J Nephrol 2003;16:787-91.
103. Deegens JK, Artz MA, Hoitsma AJ, Wetzels JF. Outcome of renal transplantation in patients with systemic lupus erythematosus. Transpl Int 2003;16:411-8.
104. Goral S, Ynares C, Shappell SB, Snyder S, Feurer ID, Kazancioglu R et al. Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare. Transplantation 2003;75:651-6.
105. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-30.